These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1096 related articles for article (PubMed ID: 30877495)

  • 61. Cytoreductive surgery without intra-peritoneal chemotherapy for metachronous colorectal peritoneal metastases.
    Ota E; Fukunaga Y; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Akiyoshi T
    World J Surg Oncol; 2024 Jul; 22(1):205. PubMed ID: 39085860
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment Strategies and Prognosis of Patients With Synchronous or Metachronous Colorectal Peritoneal Metastases: A Population-Based Study.
    Bakkers C; Lurvink RJ; Rijken A; Nienhuijs SW; Kok NF; Creemers GJ; Verhoef C; Lemmens VE; van Erning FN; De Hingh IH
    Ann Surg Oncol; 2021 Dec; 28(13):9073-9083. PubMed ID: 34076807
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study.
    Ye J; Ren Y; Wei Z; Peng J; Chen C; Song W; Tan M; He Y; Yuan Y
    Surg Oncol; 2018 Sep; 27(3):456-461. PubMed ID: 30217302
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
    Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study.
    Cascales-Campos PA; López-López V; Muñoz-Casares FC; Feliciangeli E; Torres Melero J; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Gil J
    Surg Oncol; 2016 Jun; 25(2):111-6. PubMed ID: 27312037
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer.
    Piso P; Stierstorfer K; Gerken M; Klinkhammer-Schalke M
    Int J Colorectal Dis; 2018 Nov; 33(11):1559-1567. PubMed ID: 30132068
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Towards Equal Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy and Survival in Patients with Isolated Colorectal Peritoneal Metastases: A Nationwide Population-Based Study.
    van der Ven RGFM; van den Heuvel TBM; Rovers KPB; Nienhuijs SW; Boerma D; van Grevenstein WMU; Hemmer PHJ; Kok NFM; Madsen EVE; de Reuver P; Tuynman JB; van Erning FN; de Hingh IHJT
    Ann Surg Oncol; 2024 Jun; 31(6):3758-3768. PubMed ID: 38453767
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC.
    Reghunathan M; Kelly KJ; Valasek MA; Lowy AM; Baumgartner JM
    Ann Surg Oncol; 2018 Mar; 25(3):702-708. PubMed ID: 29282599
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Gains of Chromosome 1p and 15q are Associated with Poor Survival After Cytoreductive Surgery and HIPEC for Treating Colorectal Peritoneal Metastases.
    Enblad M; Graf W; Terman A; Pucholt P; Viklund B; Isaksson A; Birgisson H
    Ann Surg Oncol; 2019 Dec; 26(13):4835-4842. PubMed ID: 31620944
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases.
    Votanopoulos KI; Russell G; Randle RW; Shen P; Stewart JH; Levine EA
    Ann Surg Oncol; 2015 Apr; 22(4):1274-9. PubMed ID: 25319583
    [TBL] [Abstract][Full Text] [Related]  

  • 72. In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival.
    Said I; Ubink I; Ewalds RSG; Arkesteijn JGT; Verheul HMW; de Wilt JHW; Dekker HM; Bremers AJA; de Reuver PR
    Ann Surg Oncol; 2022 Aug; 29(8):5256-5262. PubMed ID: 35430666
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
    Malgras B; Gayat E; Aoun O; Lo Dico R; Eveno C; Pautrat K; Delhorme JB; Passot G; Marchal F; Sgarbura O; Ferron G; Goéré D; Andre T; Pocard M;
    Ann Surg Oncol; 2018 Oct; 25(11):3271-3279. PubMed ID: 29978366
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Randle RW; Doud AN; Levine EA; Clark CJ; Swett KR; Shen P; Stewart JH; Votanopoulos KI
    Ann Surg Oncol; 2015 May; 22(5):1634-8. PubMed ID: 25120252
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Devilee RA; Simkens GA; van Oudheusden TR; Rutten HJ; Creemers GJ; Ten Tije AJ; de Hingh IH
    Ann Surg Oncol; 2016 Sep; 23(9):2841-8. PubMed ID: 27044447
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis.
    van Oudheusden TR; Braam HJ; Nienhuijs SW; Wiezer MJ; van Ramshorst B; Luyer MD; Lemmens VE; de Hingh IH
    Ann Surg Oncol; 2014 Aug; 21(8):2621-6. PubMed ID: 24671638
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diagnostic Laparoscopy as a Selection Tool for Patients with Colorectal Peritoneal Metastases to Prevent a Non-therapeutic Laparotomy During Cytoreductive Surgery.
    Hentzen JEKR; Constansia RDN; Been LB; Hoogwater FJH; van Ginkel RJ; van Dam GM; Hemmer PHJ; Kruijff S
    Ann Surg Oncol; 2020 Apr; 27(4):1084-1093. PubMed ID: 31641950
    [TBL] [Abstract][Full Text] [Related]  

  • 78. HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits?
    Hotopp T
    Surg Oncol; 2019 Mar; 28():159-166. PubMed ID: 30851894
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Braam HJ; van Oudheusden TR; de Hingh IH; Nienhuijs SW; Boerma D; Wiezer MJ; van Ramshorst B
    J Surg Oncol; 2014 Jun; 109(8):841-7. PubMed ID: 24619813
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.